Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma
Mené sur 751 patients atteints d'un astrocytome anaplasique et dont 444 présentent une mutation IDH (durée médiane de suivi : 10,9 ans), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie globale, de l'ajout de témozolomide à la radiothérapie
An anaplastic astrocytoma is a grade 3 glioma that develops from glial cells supporting nerve cells. It accounts for 2% of brain tumors and is more common among people in their 30s to 50s. Standard treatment includes surgery and radiation, with chemotherapy given during or after radiation.
Isocitrate dehydrogenase–mutated (IDHmt) tumors, first identified in 2008, are key oncogenic drivers in the majority of astrocytomas and are associated with a better disease prognosis. However, researchers had not been certain if adding temozolomide chemotherapy during and after radiotherapy for grade 3 IDHmt astrocytoma would improve survival.
CA: A Cancer Journal for Clinicians , article en libre accès, 2026